[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Laura Clague Biography and Net Worth

CFO of Travere Therapeutics

Laura Clague, CPA, has served as chief financial officer of Travere Therapeutics since November 2014. Ms. Clague has 30 years of experience as a financial executive, and oversees the company’s accounting, finance, IT and facilities functions. Previously, Ms. Clague served as chief financial officer of the San Diego and Ohio operations of Amylin Pharmaceuticals, Inc., after its acquisition by Bristol-Myers Squibb and subsequent divestiture to AstraZeneca. Prior to the acquisition, Ms. Clague was the vice president, corporate controller and principal accounting officer of Amylin for 10 years, when she also served as the chief financial officer of Amylin’s collaboration with Eli Lilly and Company.

Earlier, Ms. Clague held financial roles at Sony Electronics, Inc., Cubic Corporation and KPMG. Ms. Clague currently serves on the board of directors of Fluidigm Corporation and Genasys, Inc. Ms. Clague is a certified public accountant in the State of California, and received a bachelor’s in business administration from Menlo College.

What is Laura Clague's net worth?: The estimated net worth of Laura Clague is at least $674,316.30 as of May 10th, 2022. Ms. Clague owns 37,030 shares of Travere Therapeutics stock worth more than $674,316 as of November 21st. This net worth evaluation does not reflect any other assets that Ms. Clague may own. Learn More about Laura Clague's net worth.
How do I contact Laura Clague?: The corporate mailing address for Ms. Clague and other Travere Therapeutics executives is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. Travere Therapeutics can also be reached via phone at (888) 969-7879 and via email at [email protected]. Learn More on Laura Clague's contact information.
Has Laura Clague been buying or selling shares of Travere Therapeutics?: Laura Clague has not been actively trading shares of Travere Therapeutics within the last three months. Most recently, Laura Clague sold 825 shares of the business's stock in a transaction on Tuesday, May 10th. The shares were sold at an average price of $21.51, for a transaction totalling $17,745.75. Following the completion of the sale, the chief financial officer now directly owns 37,030 shares of the company's stock, valued at $796,515.30. Learn More on Laura Clague's trading history.
Who are Travere Therapeutics' active insiders?: Travere Therapeutics' insider roster includes Steve Aselage (Director), Sandra Calvin (CAO), Laura Clague (CFO), Eric Dube (CEO), Peter Heerma (Insider), Elizabeth Reed (SVP), Noah Rosenberg (Insider), and William Rote (SVP). Learn More on Travere Therapeutics' active insiders.
Are insiders buying or selling shares of Travere Therapeutics?: During the last year, insiders at the sold shares 19 times. They sold a total of 160,806 shares worth more than $1,943,699.05. The most recent insider tranaction occured on October, 4th when Director Gary A Lyons sold 40,000 shares worth more than $589,200.00. Insiders at Travere Therapeutics own 3.8% of the company. Learn More about insider trades at Travere Therapeutics.
Information on this page was last updated on 10/4/2024.

Laura Clague Insider Trading History at Travere Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/10/2022	Sell	825	$21.51	$17,745.75	37,030
1/31/2022	Sell	1,238	$27.40	$33,921.20
1/24/2022	Sell	2,063	$24.98	$51,533.74
1/11/2022	Sell	7,500	$27.40	$205,500.00
2/3/2021	Sell	3,625	$28.91	$104,798.75

Laura Clague Buying and Selling Activity at Travere Therapeutics

Travere Therapeutics Company Overview

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Today's Range

Now: $18.21

$17.89

$18.40

50 Day Range

MA: $16.56

$12.60

$19.85

2 Week Range

Now: $18.21

$5.12

$20.33

Volume

260,423 shs

Average Volume

1,396,979 shs

Market Capitalization

$1.42 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.7

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

From Colonial Metals | Ad

Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…

Get Your Free Gold Guide